Scholars Central

OtherPublished 13 Jul 2016

Etanercept for the treatment of axial spondyloarthritis

Authors: I-H Song, J Sieper

Clinical Investigation

Volume 3 · Issue 4 · Pages 343

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The introduction of etanercept (ETN; Enbrel®), and other TNF-blockers, has revolutionized the treatment of patients with ankylosing spondylitis. ETN, as with other approved TNF-blockers, shows good efficacy in treating spinal disease, especially if patients are treated early. Furthermore, studies involving ETN demonstrate good long-term efficacy. This review summarizes the data on ETN in the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis, and discusses topics such as its efficacy in treating extra-articular manifestations, dose modifications and immunogenicity of ETN, and switching between ETN and other TNF-blockers, as well as radiographic progression and safety.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “I-H Song”
  • BylineArticles whose byline prints “J Sieper”